Home Clinical Psychology & Psychotherapy Study Shows “Drug Holidays” Boost Sexual Health in Men on SSRIs

Study Shows “Drug Holidays” Boost Sexual Health in Men on SSRIs

Reading Time: 2 minutes

A recent clinical trial has revealed a promising strategy for men experiencing sexual dysfunction due to selective serotonin reuptake inhibitors (SSRIs) – “drug holidays”. This innovative approach involves temporarily discontinuing medication, potentially offering relief for many who grapple with this common side effect of antidepressants.

SSRIs, widely used in treating mental disorders, are often marred by the side effects of sexual dysfunction. This issue can lead to poor treatment adherence and discontinuation, posing a significant challenge in mental healthcare. Recognising this, researchers sought to explore the efficacy of drug holidays—a temporary break from medication – as a solution.

The study, conducted over eight weeks in Iran, focused on married men aged 18–50 undergoing SSRI treatment (excluding fluoxetine due to its long half-life). Participants were randomly assigned to two groups: one practicing drug holidays on weekends and the other continuing their regular medication regimen. The Male Sexual Health Questionnaire (MSHQ) and the 28-Question General Health Questionnaire (GHQ-28) assessed sexual function and mental health, respectively.

The findings were published in the journal BMC Psychiatry.

The trial, which included 63 participants, with 50 completing it, revealed significant findings:

  • The drug holiday group showed notable improvements in sexual function, including erection, ejaculation, and overall satisfaction.
  • There were no major side effects or significant changes in mental health status.
  • The control group, which continued regular medication, did not exhibit similar improvements.

These results suggest that drug holidays could be an effective method for managing SSRI-induced sexual dysfunction in men, balancing mental health treatment and sexual health.

The study highlights drug holidays as a potential strategy to increase adherence to antidepressant therapy while reducing treatment discontinuation due to sexual side effects. But the research faced limitations like a small sample size, the inclusion of only married men, and the varied SSRIs used. Further research with larger, more diverse samples and longer follow-up periods is necessary to confirm these findings and establish the safety and efficacy of drug holidays.

The study’s methodology involved a careful assessment of sexual function and mental health, ensuring that the drug holiday strategy did not negatively impact the participants’ overall well-being. The use of the MSHQ and GHQ-28 provided a comprehensive evaluation of the effects of drug holidays. The significant improvement in sexual function in the drug holiday group, without any major changes in mental health status, is a critical finding, offering a viable solution to a problem that affects many men on SSRIs.

While promising, the study’s limitations must be considered. The small sample size and the specific demographic (only married men) may limit the generalizability of the results. The variety of SSRIs used by participants also adds complexity to the findings. These factors underscore the need for further research to validate the study’s results and explore the applicability of drug holidays in a broader context.

© Copyright 2014–2034 Psychreg Ltd